Placebo News and Research

RSS

Botulinum toxin may help prevent arm tremor in people with MS

Botulinum toxin may help prevent shaking or tremor in the arms and hands of people with multiple sclerosis (MS), according to new research published in the July 3, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Vitamin D–calcium combo reduces mortality in elderly

The results of a meta-analysis of individual patient data show that vitamin D supplementation with calcium reduces mortality rates in the elderly.

2 Jul 2012

Folic acid ‘may benefit diabetics’

Folic acid supplementation can significantly reduce homocysteine levels and may therefore offer an approach for lowering cardiovascular risk among patients with Type 2 diabetes, report researchers.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

Drug trial participants should be better informed about benefits and side-effects of placebos

Research carried out at the University of Southampton has concluded that participants in drug trials should be better informed about the potential significant benefits and possible side-effects of placebos.

29 Jun 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Statins for erectile dysfunction proposed

Family doctors should offer men with erectile dysfunction treatment with a statin – not only to improve their quality of life but also to reduce their future cardiovascular risk.

28 Jun 2012

Statin effects may be gender-specific

The benefit of using statins may differ according to gender, show findings from a meta-analysis.

28 Jun 2012

Methylphenidate ‘could relieve cancer depression’

The drug methylphenidate is well tolerated among advanced cancer patients and shows promise in alleviating depression in this group, report researchers from Spain.

28 Jun 2012

Dietary fiber can improve gastrointestinal health

A University of Illinois study shows that dietary fiber promotes a shift in the gut toward different types of beneficial bacteria. And the microbes that live in the gut, scientists now believe, can support a healthy gastrointestinal tract as well as affect our susceptibility to conditions as varied as type 2 diabetes, obesity, inflammatory bowel disease, colon cancer, and autoimmune disorders such as rheumatoid arthritis.

28 Jun 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Full results from Derma Sciences’ DSC127 Phase 2 trial on diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that full results from its successful Phase 2 clinical trial with the investigational drug DSC127 in patients with diabetic foot ulcers will be published on July 5th in the July 2012 issue of Wound Repair and Regeneration.

28 Jun 2012

Anthera announces results from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

28 Jun 2012

$Chinese herbal preparation reduces fragility fractures$

Chinese herbal preparation reduces fragility fractures

Herbal Fufang – a multi-herbal preparation used in traditional Chinese medicine –increases bone mineral density and reduces fragility fractures in postmenopausal women, Chinese researchers report.

27 Jun 2012